Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 inhibitor approved in the United States, European Union, South Korea, China, and other countries for the treatment of adults with moderate to severe plaque psoriasis [6, 7, 8, 9]. The gene discussed is TYK2; the disease is psoriasis vulgaris.